From the Journals

Higher odds for preterm, C-section births seen in women with PsA


 

Are adverse outcomes linked to disease activity or treatment?

Patients in the study had a higher risk of adverse outcomes when they had a PsA diagnosis, and when they received antirheumatic treatment – but were the adverse outcomes associated with a patient’s high disease activity or need for antirheumatic treatment?

“Our interpretation is that a PsA disease that requires continued antirheumatic treatment during pregnancy is more severe than PsA that does not require treatment,” Dr. Remaeus and colleagues write. “Thus, the increased risk of adverse outcomes in pregnancies with maternal antirheumatic treatment is probably attributed to disease severity rather than an effect of the medication itself.”

Dr. Anja Strangfeld of the German Rheumatism Research Center, Berlin

Dr. Anja Strangfeld

Anja Strangfeld, MD, PhD, of the German Rheumatism Research Centre in Berlin, told this news organization that the results of the study are important because it is one of the first to report differences in risk in pregnancy outcomes for women with and without PsA.

“The information is relevant to guide rheumatologists in advising patients with PsA when planning the first or subsequent pregnancies,” she said. “The results are reassuring in reporting that the elevated risk for PsA patients for adverse pregnancy outcomes is low in patients not in need of antirheumatic medication, presumably in low-disease activity.”

However, the study is still unclear on whether the association with adverse pregnancy outcomes in patients is the result of higher disease activity or the need for antirheumatic treatment, she explained.

“It was only hypothesized that those patients under bDMARD treatment are/were in high disease activity. There [is] no information on disease activity in the data sources, which limits the results,” she said. “The investigation still does not solve the important question – if adverse pregnancy outcomes are rather related to high disease activity or the medication to treat this situation.”

There was no specific funding for this study. The study authors and Dr. Strangfeld have disclosed no relevant financial relationships.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

Better COVID-19 outcomes confirmed in TNF inhibitor users
MDedge Dermatology
Disease activity-guided dose optimization of TNF inhibitors safe and effective in PsA
MDedge Dermatology
Psoriasis patients initiating biologics more likely to develop PsA
MDedge Dermatology
PsA: Phase 3 confirms rapid and significant response of secukinumab on synovitis
MDedge Dermatology
Study identifies different patient priorities when selecting biologics for PsA
MDedge Dermatology
Psoriasis patients with more severe disease at higher risk of developing PsA
MDedge Dermatology
PsA: Long-term apremilast offers clinical benefits in ACR20 nonresponders
MDedge Dermatology
Itch relief major contributor for tofacitinib-mediated–improved QoL in PsA
MDedge Dermatology
Predictors and risk factors for PsA transition in patients with psoriasis
MDedge Dermatology
Effect of background methotrexate dose on tofacitinib efficacy in patients with PsA
MDedge Dermatology